The Liver X Receptor Agonist GW3965 Improves Recovery from Mild Repetitive Traumatic Brain Injury in Mice Partly through Apolipoprotein E
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Traumatic brain injury (TBI) increases Alzheimer's disease (AD) risk and leads to the deposition of neurofibrillary tangles and amyloid deposits similar to those found in AD. Agonists of Liver X receptors (LXRs), which regulate the expression of many genes involved in lipid homeostasis and inflammation, improve cognition and reduce neuropathology in AD mice. One pathway by which LXR agonists exert their beneficial effects is through ATP-binding cassette transporter A1 (ABCA1)-mediated lipid transport onto apolipoprotein E (apoE). To test the therapeutic utility of this pathway for TBI, we subjected male wild-type (WT) and apoE-/- mice to mild repetitive traumatic brain injury (mrTBI) followed by treatment with vehicle or the LXR agonist GW3965 at 15 mg/kg/day. GW3965 treatment restored impaired novel object recognition memory in WT but not apoE-/- mice. GW3965 did not significantly enhance the spontaneous recovery of motor deficits observed in all groups. Total soluble Aβ(40) and Aβ(42) levels were significantly elevated in WT and apoE-/- mice after injury, a response that was suppressed by GW3965 in both genotypes. WT mice showed mild but significant axonal damage at 2 d post-mrTBI, which was suppressed by GW3965. In contrast, apoE-/- mice showed severe axonal damage from 2 to 14 d after mrTBI that was unresponsive to GW3965. Because our mrTBI model does not produce significant inflammation, the beneficial effects of GW3965 we observed are unlikely to be related to reduced inflammation. Rather, our results suggest that both apoE-dependent and apoE-independent pathways contribute to the ability of GW3965 to promote recovery from mrTBI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Center for Injury Prevention and Control (U.S.). Division of Injury Response., Faul, M., Wald, M. M., Wu, L., & Coronado, V. G. (2010) · doi:10.15620/cdc.5571 · Cited by 3,494
A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data
Ennaceur, A., & Delacour, J. (1988) · Behavioural Brain Research · doi:10.1016/0166-4328(88)90157-x · Cited by 3,223
The novel object recognition memory: neurobiology, test procedure, and its modifications
Antunes, M., & Biala, G. (2012) · Cognitive Processing · doi:10.1007/s10339-011-0430-z · Cited by 2,390 · cited 2×
“Discrimination between the novel and familiar objects was determined using the discrimination index (DI) [48].”
MethodProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Pathophysiology of traumatic brain injury
Werner, C., & Engelhard, K. (2007) · British Journal of Anaesthesia · doi:10.1093/bja/aem131 · Cited by 1,712
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Goldstein, L. E., Fisher, A. M., Tagge, C. A., Zhang, X.-L., Velisek, L., Sullivan, J. A., Upreti, C., Kracht, J. M., Ericsson, M., Wojnarowicz, M. W., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003716 · Cited by 958 · cited 2×
“ductance accompanied by tau pathology, myelinated axonopathy, microvasculopathy, and neuroinflammation [62].”
BackgroundApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Cited by
Apolipoprotein E in Alzheimer's Disease: An Update
Yu, J.-T., Tan, L., & Hardy, J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014300 · Cited by 394
“In addition, LXRs, RXRs, or PPARγ agonists, such as T0901317, GW3965, bexarotene, and pioglitazone, could reduce amyloid levels and improve cognitive performance in AD mice (Cramer et al. 2012, Donkin et al. 2010, Jiang et al. 2008, Mandrekar-Colucci et al. 2012, Namjoshi et al. 2013).”
BackgroundMolecular mechanisms of cognitive dysfunction following traumatic brain injury
Walker, K. R., & Tesco, G. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00029 · Cited by 265
Shao, F., Wang, X., Wu, H., Wu, Q., & Zhang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.825086 · Cited by 250
“Furthermore, LXR activation by synthetic agonists have been reported to reduce Aβ accumulation, decrease lesion volume, lessen axonal impairment, and promote functional recovery in mouse models of TBI (Loane et al., 2011; Namjoshi et al., 2013).”
BackgroundGe, X., Guo, M., Hu, T., Li, W., Huang, S., Yin, Z., Li, Y., Chen, F., Zhu, L., Kang, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.017 · Cited by 242
“Besides, ApoE enhances the proteolytic breakdown of Ab in AD and rmTBI.(37,50) As to the present study, the expression of ApoE in injured neurons is promoted by microglial exosomal miR-124-3p via targeting Rela, which functions as an inhibitory transcription factor.”
BackgroundNamjoshi, D. R., Cheng, W. H., McInnes, K. A., Martens, K. M., Carr, M., Wilkinson, A., Fan, J., Robert, J., Hayat, A., Cripton, P. A., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-55 · Cited by 195
Self-citationLXR Regulation of Brain Cholesterol: From Development to Disease
Courtney, R., & Landreth, G. E. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.03.018 · Cited by 190
“LXRs have been implicated in the regulation of a wide array of brain processes and dysfunction: anxiety, through the regulation of GABA synthesis [58]; neuroprotection against ethanol exposure during cerebellar development [59]; and recovery after traumatic brain injury, possibly through apoE-dependent effects on axon…”
BackgroundApoE Lipidation as a therapeutic target in Alzheimer’s disease
Lanfranco, M. F., Ng, C. A., & Rebeck, G. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176336 · Cited by 189
Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities
Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91
The Role of Cholesterol Metabolism in Alzheimer’s Disease
Sun, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8749-y · Cited by 70
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Targeting Apolipoprotein E for Alzheimer’s Disease: An Industry Perspective
Suidan, G. L., & Ramaswamy, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092161 · Cited by 42
“Increasing astrocytic abca1 expression and the resulting increase in apoE lipidation has been shown to have beneficial effects on axonal damage in a traumatic brain injury mouse model [30,31].”
BackgroundBennett, R. E., Esparza, T. J., Lewis, H. A., Kim, E., Mac Donald, C. L., Sullivan, P. M., & Brody, D. L. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31828e24ab · Cited by 40
Jan, A., Karasinska, J. M., Kang, M. H., de Haan, W., Ruddle, P., Kaur, A., Connolly, C., Leavitt, B. R., Sorensen, P. H., & Hayden, M. R. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.05.007 · Cited by 28
LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice
Stukas, S., Freeman, L., Lee, M., Wilkinson, A., Ossoli, A., Vaisman, B., Demosky, S., Chan, J., Hirsch-Reinshagen, V., Remaley, A. T., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m049940 · Cited by 9
Self-citationSuenaga, M., Furuta, A., Wakabayashi, K., Saibara, T., & Matsunaga, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.04.028 · Cited by 4
Metadata
- Authors
- Namjoshi, D. R., Martin, G., Donkin, J., Wilkinson, A., Stukas, S., Fan, J., Carr, M., Tabarestani, S., Wuerth, K., Hancock, R. E. W., & Wellington, C. L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-17
- Volume
- 8
- Issue
- 1
- Pages
- e53529
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1968155219
- Cited by
- 51
- References
- 31
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.